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Abstract 
Background: MicroRNAs are regulatory molecules and suggested as non-invasive biomarkers for molecular diagnos-
tics and prognostics. Altered expression levels of specific microRNAs are associated with hepatitis B virus infection and 
hepatocellular carcinoma. We previously identified differentially expressed microRNAs with liver-specific target genes 
in plasma from children with chronic hepatitis B. To further understand the biological role of these microRNAs in the 
pathogenesis of chronic hepatitis B, we have used the human liver cell line HepG2, with and without HBV replication, 
after transfection of hepatitis B virus expression vectors. RT-qPCR is the preferred method for microRNA studies, and a 
careful normalisation strategy, verifying the optimal set of reference genes, is decisive for correctly evaluating micro-
RNA expression levels. The aim of this study was to provide valid reference genes for the human HCC-derived cell line 
HepG2.
Results: A panel of 739 microRNAs was screened to identify the most stably expressed microRNAs, followed by a 
PubMed search identifying microRNAs previously used as reference genes. Sixteen candidate reference genes were 
validated by RT-qPCR. Reference gene stabilities were calculated first by standard deviations of ΔCt values and then by 
geNorm and NormFinder analyses, taking into account the amplification efficiency of each microRNA primer set. The 
optimal set of reference genes was verified by a target analysis using RT-qPCR on miR-215-5p.
Conclusion: We identified miR-24-3p, miR-151a-5p, and miR-425-5p as the most valid combination of reference 
genes for microRNA RT-qPCR studies in our hepatitis B virus replicating HepG2 cell model.
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Background
MicroRNAs are suggested as non-invasive biomarkers 
for molecular diagnostics and prognostics, and some 
microRNAs show promising results as therapeutic tar-
gets in human trials [1–3]. A single microRNA can have 
multiple downstream targets and affect a number of dif-
ferent networks and pathways [4, 5]. Even small changes 
in microRNA expression may therefore have implications 
for gene regulation in various physiological and patho-
physiological states [1, 6].
Hepatitis B virus (HBV) infection is a world-wide prob-
lem and approximately 240 million people live with a 
chronic HBV infection. HBV is one of the leading causes 
of hepatocellular carcinoma (HCC) and is responsible for 
the death of around 780,000 people each year [7].
MicroRNAs are thought to play an important role in 
early HBV infection, chronic HBV infection, and HBV-
related cirrhosis and HCC [8–10]. Chronic hepati-
tis B (CHB) in children is associated with a high risk of 
developing HCC over time [11, 12]. Current knowledge 
on the pathogenesis at the molecular level is, however, 
limited [13]. We previously identified a panel of differ-
entially expressed microRNAs in plasma from children 
with CHB [14] and furthermore showed that a number of 
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the identified microRNAs had liver-specific target genes 
[15]. Liver tissue samples are unavailable as the majority 
of children with CHB are asymptomatic. Instead we use 
an in vitro HBV-replicating liver cell model to investigate 
the biological role of microRNAs with a possible influ-
ence on the pathogenesis of CHB in children.
RT-qPCR is often the preferred method for microRNA 
expression studies because of its sensitivity, flexibility, 
wide dynamic range, accuracy, and high throughput [16, 
17]. Correct normalisation of microRNA RT-qPCR data 
is important to avoid erroneous conclusions [18]. Cur-
rently, there is no standardised normalisation strategy 
for microRNA RT-qPCR expression studies [19]. The 
small nuclear RNA U6 is frequently used as a reference 
gene (RG) in such studies [20]. Another strategy that 
has achieved general acceptance in RT-qPCR studies is 
identification of valid RGs by computer software such as 
geNorm and NormFinder [21, 22].
The present study was conducted to identify suitable 
RGs for microRNA expression studies in a human HCC-
derived cell line (HepG2 tet-on), with and without HBV 
replication, after transfection of HBV expression vectors. 
We performed a systematic evaluation and identified 
miR-24-3p, miR-151a-5p, and miR-425-5p as the most 
valid combination of RGs in our model system. Results 
were verified by assessment of miR-215-5p, which is 
known to have a role in the pathogenesis of HBV infec-
tion [23, 24].
Results and discussion
Identification of candidate reference genes
Experiments were performed in the human HCC-derived 
cell line HepG2 tet-on. HBV replication was introduced 
by a doxycycline-inducible vector containing the 3091 
HBV genome [25].
We applied a human microRNA PCR panel (Exiqon, 
Vedbaek, Denmark) to identify a number of stably 
expressed microRNAs. The microRNA panel included 
739 microRNAs, and according to the manufacturer 
it included microRNAs that are either (1) generally 
more highly expressed, (2) more likely to be differen-
tially expressed in disease, or (3) more often cited in 
the literature. We investigated the overall expression 
at two different time points (48 and 72  h) in the con-
trol HepG2 tet-on cell line and the HBV-replicating cell 
line (DOXY) (See Additional file  1 Figure S1  for heat-
map, and Additional file 2 Table S1 for raw CT values). 
We identified the presence of 137 microRNAs, using 
an exclusion value of CT ≥  32. We then evaluated the 
overall stability of each microRNA by calculating the 
standard deviation (SD) for all samples. MicroRNAs 
with SD values below 0.2 (35 microRNAs in total) were 
further investigated in a PubMed search to identify 
the microRNAs previously used as RGs. On this basis, 
13 microRNAs (miR-17-5p, -24-3p, -26b-5p, -93-5p, 
-103a-3p, -106a-5p, -130b-3p, -151a-5p, -191-5p, -221-
3p, -425-5p, -940 and let-7d-5p) were selected as can-
didate RGs (Table  1). Three small nuclear non-coding 
RNAs (U6 snRNA, SNORD38B, and SNORD49A) that 
are often used as RGs in microRNA expression studies 
[20, 26–28] were included to test for the importance of 
structural similarities, when choosing appropriate RGs. 
In total, 16 non-coding RNAs were subjected to further 
investigation.
Individual RT‑qPCR and amplification efficiency
The selected candidate RGs were analysed by RT-qPCR. 
MiR-103a-3p and miR-let-7d-5p were excluded from 
further analyses because of CT values > 32. Mean CT val-
ues ± SD are shown in Table 2.
We evaluated the primer amplification efficiencies 
of the remaining 14 non-coding RNAs. The optimal 
primer efficiency is 2.0 corresponding to a doubling of 
the target in each cycle. In the present setup we used 
Locked Nucleic Acid (LNA) primers [29] and obtained 
amplification efficiencies from 1.8 to 2.7 (efficiencies 
and R2 values are listed in Table 3). LNA primers have 
been shown to have low amplification efficiencies [30] 
but were used in this study to ensure high affinity, spec-
ificity, and stability with regards to the microRNAs of 
interest [17, 31]. Calculated primer efficiencies were 
used in both our geNorm and NormFinder analyses 
[32].
Table 1 Candidate reference genes for microRNA normali-
sation
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Stability analysis by ∆Ct, geNorm and NormFinder
Overall expression stability of our 14 candidate RGs 
was evaluated by calculating the SD of the ∆Ct values 
from samples taken over time (24–96 h) in the cell lines: 
HepG2 tet-on, DOXY, and its negative control contain-
ing the non-replicating HBV genome. Top three were 
miR-151a-5p, miR-24-3p and miR-93-5p with SD val-
ues  <  0.3. geNorm selects the optimal number of RGs 
based on the calculation of a stability value (M) and a 
pairwise variation value (V). In our analysis, miR-93-5p 
and miR-151-3p were identified as the most stable RG 
pair (M  =  0.15) (Fig.  1a). A pairwise variation analysis 
showed that two RGs should suffice (V = 0.06), but add-
ing a third gene (miR-425-5p) would improve normalisa-
tion (V = 0.05) (Fig. 1b). Three is also the lowest number 
of RGs recommended for use in microRNA expression 
studies [33]. One microRNA, miR-940, had an M-value 
above the exclusion limit of 1.5 (M  =  5.43), making it 
unsuitable as a RG (Fig.  1a). NormFinder identifies the 
best normalisation gene from a group of candidates by 
calculating a stability value for each candidate. Our anal-
ysis revealed miR-93-5p as the best RG, with a stability 
value of 0.04. The best combination of genes was miR-
130b-3p and miR-24-3p, lowering the stability value to 
0.025 (Table 4). 
A top-five comparison between the three approaches 
examined above found miR-151a-5p, miR-93-5p, miR-
24-3p, and miR-425-5p to be the best RGs. According to 
geNorm three RGs are sufficient for optimal normalisa-
tion. Taking the amplification efficiencies into account 
(Table  3), the best combination to use in the present 
model system is miR-151a-5p, miR-425-5p, and miR-
24-3p (Fig. 2).
It is worth noting that U6, which is often used as a RG 
in microRNA RT-qPCR studies, had the most deviated 
amplification efficiency (E  =  2.761) and ranked last or 
second to last in the three analyses.
Validation of the cell model system
We make use of the human liver cell model HepG2 tet-on 
for our in vitro studies due to lack of primary tissue from 
asymptomatic children with CHB. We introduced a doxy-
cycline-inducible vector containing the HBV genome and 
the transactivator controlling mature virus production. 
Two genes work independently of this transactivator: The 
S gene, coding for the three surface proteins present in 
the viral envelope, and the X gene found to have onco-
genic properties [34]. These proteins are continuously 
expressed independently of doxycycline-induction.
To evaluate our model system we investigated the 
expression of the most abundant liver specific micro-
RNA, miR-122. miR-122 has been found to inhibit the 
expression and replication of HBV, and it is found down-
regulated upon HBV infection, possibly facilitating 
viral replication and persistence [35–37]. We found the 
expression of miR-122-5p significantly decreased upon 
the insertion of the HBV plasmid independent of HBV 
replication [CT  =  24 in the HepG2 tet-on cell line and 
CT = 34 in the cell lines containing the HBV genome with 
or without induction (p < 0.0001)]. This is in accordance 
with results from previous studies identifying the HBx 
protein as a negative regulator of miR-122 expression [37, 
Table 2 Mean Ct values for  the 16 candidate reference 
genes
Reference genes with CT values > 32 were excluded from further analyses














U6 snRNA 23.78 1.56
SNORD38B 23.36 0.38
SNORD49B 22.91 0.38
Table 3 PCR amplification efficiencies
 microRNA Standard curve E = 10−1/slope




miR-130b-3p −3.829 0.996 1.825 82
miR-93-5p −3.805 0.999 1.832 83
miR-221-3p −3.765 0.996 1.843 84
miR-106a-5p −3.746 0.999 1.849 85
miR-425-5p −3.745 0.989 1.849 85
miR-191-5p −3.688 0.988 1.867 87
miR-24-3p −3.577 0.994 1.904 90
miR-151a-5p −3.576 0.997 1.904 90
miR-940 −3.316 0.993 2.003 100
SNORD38B −3.231 0.996 2.040 104
miR-26b-5p −2.975 0.948 2.168 117
miR-17-5p −2.884 0.933 2.222 122
SNORD49A −2.836 0.991 2.252 125
U6 snRNA −2.267 0.791 2.761 176
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38], and the constitutive expression of the HBx protein in 
the transfected cell lines. This result supports the usage 
of this cell model system to investigate the biological role 
of microRNAs in HBV infection.
Validation of reference genes
To assess the reliability of our selected RGs, we per-
formed a target analysis on miR-215-5p, previously 
found to be up-regulated in CHB in children and adults 
as well as in HBV-related  HCC [14, 23, 24, 39]. We 
studied the expression of miR-215-5p in HepG2 cells 
with and without HBV replication by RT-qPCR after 
48 h of doxycycline treatment, and we normalised using 
miR-24-3p, miR-151a-5p, and miR-425-5p. Fold change 
was calculated using the 2−∆∆Ct method [40]. We found 
a significant up-regulation of miR-215-5p in the DOXY 
cell line compared to the control HepG2 tet-on cell 
line (0.2 fold, p  =  0.04). We also normalised against 
the commonly used RG U6 and found miR-215-5p to 
5.43
0.66
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Determination of the optimal number of control genes for normalization
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b
Fig. 1 geNorm analysis of candidate reference genes. a Ranking of reference genes according to the average expression stability M. A stepwise 
exclusion strategy identified miR-93-5p and miR-151a-5p as the most stable reference gene pair. b Determination of the optimal number of refer-
ence genes for normalisation, concluding that top three most stable reference genes would suffice for correct normalisation
Table 4 NormFinder results. Candidate reference genes 















14 U6 snRNA 1.427
Best combination miR-130b-3p/miR-24-3p 0.025
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be up-regulated by 11.2 fold (p  =  0.01). The raw CT 
values showed approximately 1 cycle between HepG2 
tet-on and DOXY. U6 is thus not a robust RG in this 
model system. Several authors have expressed concern 
about the use of this specific spliceosomal RNA as RG 
in microRNA studies because of its variability in struc-
ture and abundance as well as its often high degree 
of variance across samples [19, 20, 41, 42]. Our study 
demonstrates the importance of correct normalisation 
in microRNA expression studies, where even small 
changes in expression can have a vast downstream 
effect [5]. Comparison across studies requires validated 
RGs to avoid analytical errors and contradictory results 
[16, 19].
Conclusion
We evaluated 16 small non-coding RNAs as possible 
RGs in a HBV-replicating liver cell line using ∆CT and 
the two software algorithms geNorm and NormFinder. 
We identified miR-24-3p, miR-151a-5p, and miR-425-5p 
as the most valid combination of RGs to use for micro-
RNA studies in this HBV-replicating HepG2 cell system 
and confirmed their validity with miR-215-5p. This result 
establishes a solid foundation for further studies in this 
cell culture model.
Methods
Cell lines and cell culture
The HepG2 tet-on Advanced Cell Line was purchased 
from Clontech (California, USA), cultured in DMEM 
media with 2  % fetal calf serum (FCS), 1  % penicillin/
streptomycin, and G418 (100  µg/ml) at 37° C with 5  % 
CO2. To produce an HBV-replicating cell line, we intro-
duced a doxycycline-inducible vector that contained 
the transactivator and an HBV genome encoding for 
HBV genotype D (ayw3 serotype) [25, 43]. The transac-
tivator controls the synthesis of the HBV pregenomic 
mRNA and thus expression of the Polymerase gene and 
the PreCore/Core gene, while the Surface proteins gene 
and the X gene are transcribed continuously using their 
individual promoters. HBV replication was activated by 
applying doxycycline (1 µg/ml) to the media.
Verification of viral replication
Media and cells were sampled at 7 time points at 12  h 
intervals (24–96  h). Media was changed following the 
48 h sampling to ensure optimal growth conditions. All 
cell lines were tested for HBV replication prior to further 
analyses. HBsAg was measured from the media using 
an in-house sandwich ELISA [C20/2, sample, Anti-HBs-
Biotin, Streptavidin-Peroxidase and substrate (OPD)] as 
previously described [44]. The cell lines transfected with 
the vector containing the HBV genome with and without 
doxycycline showed similar amounts of HBsAg in their 
media, corresponding to the design explained in the sec-
tion above. HBV DNA was only measured in media from 
the HBV-replicating cell line (data not shown).
RNA extraction and cDNA synthesis
Total RNA was extracted from cell lines using the 
miRNeasy Mini Kit (Qiagen, Hilden, Germany) in 
accordance with the manufacturer’s instructions, with 
minor modifications (200 µL chloroform was added, and 
after samples were applied to RNeasy Mini spin columns 
all centrifugation steps were performed at room tem-
perature (RT) at 13,000×g). Elution was performed once 
with 50 µL RNase-free water. RNA concentrations were 
determined and evaluated using the NanoDrop 2000c 
spectrophometer (Thermo Scientific Waltham, Mas-
sachusetts, USA), measuring the absorbance at 260  nm 
as well as the absorbance ratio 260/280 nm to check for 
proper RNA quality. RNA samples were stored at −80° C.
cDNA synthesis was performed using the Universal 
cDNA Synthesis Kit II (Exiqon, Vedbaek, Denmark) in 
accordance with the manufacturer’s instructions and 
conducted on a GeneAmp PCR System 9700 (Applied 
Biosystems, Carlsbad, California, USA). 10 ng RNA was 
used for each cDNA synthesis, and blank samples with 
H2O as template were included. cDNA was stored at 
−20° C until further use.
Quantitative real‑time PCR
microRNA PCR panels
microRNA expressions were analysed in the cell lines 
using human microRNA PCR Panels (Human Panel I and 
II V2.M) and miRCURY LNA™ Universal RT microRNA 
PCR system (Exiqon, Vedbaek, Denmark) as described 
Fig. 2 Venn diagram showing the top five candidates from the three 
different approaches (∆Ct, geNorm and NormFinder) and their overlap
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previously [14]. To further narrow down the putative RG 
candidates, a PubMed search was performed on each 
candidate to identify the microRNAs that have previously 
been used as RGs in at least one publication.
Individual RT‑qPCR
Quantification of microRNA expression levels were per-
formed by RT-qPCR using the miRCURY LNA™ Univer-
sal RT microRNA PCR system and specific microRNA 
LNA™ PCR primer sets (Exiqon, Vedbaek, Denmark). 
Specific microRNA target sequences are shown in 
Table  1. cDNA was diluted 80× and run in accordance 
with Exiqon’s instructions manual on a CFX384 Real-
Time thermal cycler (Biorad, Hercules, California, USA). 
Each sample was run in duplicate, and negative con-
trols with no-template and blanks as well as a spike-in, 
UniSp6, were assayed in each run.
Amplification efficiency
Amplification efficiency for each microRNA LNA™ PCR 
primer set was determined by standard curve analysis. 
Dilution series were made from a pool of cDNA includ-
ing samples from all cell lines and all time points. Each 
sample was run in duplicate, and blank samples were 
included as negative controls. A CT cut-off value was set 
to 36 for all primer efficiency analyses. Standard curve 
analyses were performed in duplicate, and average 
amplification efficiencies were used for further analyses.
Analysis of RT‑qPCR data
Expression stability of the testet RGs was analysed 
using two widely applied algorithms: geNorm [21] and 
NormFinder [22]. The geNorm algorithm calculates an 
M-value that represents a gene’s variation compared 
to other candidate genes. A stepwise exclusion strat-
egy identifies the two most stable genes. A candidate 
RG with an M-value above 1.5 is not considered a suit-
able RG. geNorm also calculates a V-value that deter-
mines the optimal number of RGs for normalisation. 
Starting with the two most stably expressed genes, a 
third, fourth, fifth, etc. is added, illustrating the lev-
els of variation in average reference gene stability. A 
V-score below 0.15 is adequate for normalisation. The 
NormFinder algorithm calculates a stability value. The 
gene with the lowest stability value is determined to 
be the most stable RG. NormFinder provides both the 
best stable RG as well as the best stable pair of RGs. 
This is done by taking the different subgroups into 
account, estimating the inter-group and intra-group 
variations across the samples, identifying potential 
co-regulation between the candidates in the different 
subgroups.
Statistics
All data is represented as raw data or as mean  ±  SD. 
Statistical analyses were performed in GraphPad Prism 
6 using the unpaired Student’s t test (two-tailed). p-val-
ues < 0.05 were considered significant.
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